Opioid use disorder in two samples of the Lebanese population: scale validation and correlation with sleep and mood disorders.

Humans Cross-Sectional Studies Mood Disorders Opioid-Related Disorders Analgesics, Opioid Sleep Hypnotics and Sedatives Reproducibility of Results Surveys and Questionnaires
Arabic Lebanon Opioid risk Tool Opioid use disorder Scale validation Sleep disorders

Journal

BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559

Informations de publication

Date de publication:
01 11 2023
Historique:
received: 05 03 2023
accepted: 24 10 2023
medline: 3 11 2023
pubmed: 2 11 2023
entrez: 2 11 2023
Statut: epublish

Résumé

The revised Opioid Risk Tool (ORT-OUD) is a brief, self-report scale designed to provide clinicians with a simple, validated method to screen for the risk of developing an Opioid Use Disorder (OUD) in patients without a prior history of substance abuse. This study aimed to translate and validate the Arabic version of ORT-OUD in the Lebanese population and assess its clinical validity in a sample of patients with OUD. This cross-sectional study in the Lebanese population used several validated scales to assess the risk of OUD, including the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). Other tools evaluated chronotype and sleep and mood disturbances. Principal component analysis with Varimax rotation was applied to assess ORT-OUD construct validity. Convergent validity with the Arabic version of ASSIST was evaluated. The ORT-OUD criterion validity was then assessed in a clinical sample of patients with OUD. This study included 581 participants. The prevalence of the OUD risk in the Lebanese population using the ORT-OUD scale and the ASSIST-opioids scale was estimated at 14.5% and 6.54%, respectively. No items of the ORT-OUD were removed; all items converged over a solution of four factors with an eigenvalue > 1, explaining a total of 68.2% of the variance (Cronbach's alpha = 0.648). The correlation coefficients between the ORT-OUD total score and ASSIST subscales were as follows: ASSIST-opioids (r = 0.174; p = < 0.001), ASSIST-sedatives (r = 0.249; p < 0.001), and ASSIST-alcohol (r = 0.161; p = < 0.001). ORT-OUD clinical validation showed a correlation with ASSIST-opioids (r = 0.251; p = 0.093) and ASSIST-sedatives (r = 0.598; p < 0.001). Higher ORT-OUD scores were associated with a family and personal history of alcohol and substance consumption and higher insomnia and anxiety scores. This study is the first to validate the Arabic version of ORT-OUD in the Lebanese population, an essential step towards improving the detection and management of OUD in this population.

Sections du résumé

BACKGROUND
The revised Opioid Risk Tool (ORT-OUD) is a brief, self-report scale designed to provide clinicians with a simple, validated method to screen for the risk of developing an Opioid Use Disorder (OUD) in patients without a prior history of substance abuse. This study aimed to translate and validate the Arabic version of ORT-OUD in the Lebanese population and assess its clinical validity in a sample of patients with OUD.
METHODS
This cross-sectional study in the Lebanese population used several validated scales to assess the risk of OUD, including the Alcohol, Smoking, and Substance Involvement Screening Test (ASSIST). Other tools evaluated chronotype and sleep and mood disturbances. Principal component analysis with Varimax rotation was applied to assess ORT-OUD construct validity. Convergent validity with the Arabic version of ASSIST was evaluated. The ORT-OUD criterion validity was then assessed in a clinical sample of patients with OUD.
RESULTS
This study included 581 participants. The prevalence of the OUD risk in the Lebanese population using the ORT-OUD scale and the ASSIST-opioids scale was estimated at 14.5% and 6.54%, respectively. No items of the ORT-OUD were removed; all items converged over a solution of four factors with an eigenvalue > 1, explaining a total of 68.2% of the variance (Cronbach's alpha = 0.648). The correlation coefficients between the ORT-OUD total score and ASSIST subscales were as follows: ASSIST-opioids (r = 0.174; p = < 0.001), ASSIST-sedatives (r = 0.249; p < 0.001), and ASSIST-alcohol (r = 0.161; p = < 0.001). ORT-OUD clinical validation showed a correlation with ASSIST-opioids (r = 0.251; p = 0.093) and ASSIST-sedatives (r = 0.598; p < 0.001). Higher ORT-OUD scores were associated with a family and personal history of alcohol and substance consumption and higher insomnia and anxiety scores.
CONCLUSIONS
This study is the first to validate the Arabic version of ORT-OUD in the Lebanese population, an essential step towards improving the detection and management of OUD in this population.

Identifiants

DOI: 10.1186/s12888-023-05304-8 PMID: 37914993 PMC: PMC10619223
pubmed: 37914993
doi: 10.1186/s12888-023-05304-8
pii: 10.1186/s12888-023-05304-8
pmc: PMC10619223
doi:

Substances chimiques

Analgesics, Opioid 0
Hypnotics and Sedatives 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

797

Informations de copyright

© 2023. The Author(s).

Références

Gen Hosp Psychiatry. 1997 Jul;19(4):245-50
pubmed: 9327253
JAMA Psychiatry. 2021 Feb 1;78(2):151-160
pubmed: 33175090
J Gen Intern Med. 2002 Mar;17(3):173-9
pubmed: 11929502
Neuroreport. 2002 Jul 2;13(9):1097-106
pubmed: 12151749
J Subst Abuse Treat. 2013 Jul;45(1):38-43
pubmed: 23313145
Addict Behav. 2019 Jan;88:48-55
pubmed: 30142484
Pain. 2004 Nov;112(1-2):65-75
pubmed: 15494186
Gen Hosp Psychiatry. 2008 Mar-Apr;30(2):93-9
pubmed: 18291290
Drug Alcohol Depend. 2011 May 1;115(1-2):62-6
pubmed: 21144676
Drug Alcohol Depend. 2015 Jan 1;146:17-23
pubmed: 25454405
Lancet. 2020 Oct 31;396(10260):1380-1382
pubmed: 32919521
Chronobiol Int. 2020 Jan;37(1):111-122
pubmed: 31724437
Psychiatry Res. 1989 May;28(2):193-213
pubmed: 2748771
Biol Psychiatry. 1996 Mar 15;39(6):411-8
pubmed: 8679786
J Pain Symptom Manage. 2004 May;27(5):440-59
pubmed: 15120773
Psychopharmacology (Berl). 1999 Feb;141(4):385-94
pubmed: 10090646
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
Pain Med. 2005 Nov-Dec;6(6):432-42
pubmed: 16336480
Sci Transl Med. 2022 Jun 22;14(650):eabn8238
pubmed: 35731889
Minerva Anestesiol. 2020 Jul;86(7):693-695
pubmed: 32154683
J Subst Abuse Treat. 2017 Jun;77:26-30
pubmed: 28476267
Disaster Med Public Health Prep. 2022 Oct;16(5):2200-2201
pubmed: 34789353
J Addict Dis. 2005;24(4):17-29
pubmed: 16368654
Indian J Psychol Med. 2018 Nov-Dec;40(6):556-561
pubmed: 30533952
Arch Intern Med. 2006 Oct 23;166(19):2087-93
pubmed: 17060538
J Appl Psychol. 1989 Oct;74(5):728-38
pubmed: 2793773
Curr Opin Psychol. 2019 Dec;30:17-23
pubmed: 30711906
Issues Ment Health Nurs. 2017 Jul;38(7):562-569
pubmed: 28436706
J Sleep Res. 2013 Feb;22(1):89-95
pubmed: 22978579
Drug Alcohol Depend. 2013 Oct 1;132(3):580-6
pubmed: 23688843
Drug Alcohol Depend. 2008 Sep 1;97(1-2):150-7
pubmed: 18499354
Acta Psychiatr Scand. 1983 Jun;67(6):361-70
pubmed: 6880820
Addict Sci Clin Pract. 2016 Apr 26;11(1):9
pubmed: 27117064
Front Public Health. 2021 Aug 16;9:704678
pubmed: 34485230
Alcohol Clin Exp Res. 2017 Jun;41(6):1154-1165
pubmed: 28421617
J Gen Intern Med. 2011 Sep;26(9):958-64
pubmed: 21347877
J Addict Med. 2014 Nov-Dec;8(6):395-8
pubmed: 25369939
Drug Alcohol Depend. 2017 Sep 1;178:501-511
pubmed: 28719884
J Pain. 2006 Sep;7(9):671-81
pubmed: 16942953
Br J Psychol. 2014 Aug;105(3):399-412
pubmed: 24844115
Lancet. 2008 Sep 27;372(9644):1137-8
pubmed: 18942175
Curr Opin Psychiatry. 2021 Jul 1;34(4):405-412
pubmed: 33901060
Drug Alcohol Depend. 2013 Sep 1;132(1-2):95-100
pubmed: 23410617
Soc Work Public Health. 2013;28(3-4):194-205
pubmed: 23731414
Eur Addict Res. 2013;19(4):202-10
pubmed: 23391856
J Pain. 2019 Jul;20(7):842-851
pubmed: 30690168
Pain. 2007 Jul;130(1-2):144-56
pubmed: 17493754
Drug Alcohol Depend. 2012 Feb 1;121(1-2):110-7
pubmed: 21924844
J Opioid Manag. 2022 Mar-Apr;18(2):161-166
pubmed: 35476885
Pain. 2007 Jun;129(3):355-362
pubmed: 17449178
BMC Psychiatry. 2022 Aug 5;22(1):532
pubmed: 35931970
Int J Chronobiol. 1976;4(2):97-110
pubmed: 1027738
Sleep Med. 2001 Jul;2(4):297-307
pubmed: 11438246
Drug Alcohol Depend. 2006 Apr 28;82(2):103-10
pubmed: 16154297
Sleep. 1991 Dec;14(6):540-5
pubmed: 1798888
J Clin Psychiatry. 2016 Jun;77(6):772-80
pubmed: 27337416
Drug Alcohol Depend. 2010 Dec 1;112(3):226-33
pubmed: 20708349
Addict Behav. 2014 Mar;39(3):520-31
pubmed: 24333033
J Med Liban. 2013 Oct-Dec;61(4):210-5
pubmed: 24428075
J Pain Symptom Manage. 2006 Sep;32(3):287-93
pubmed: 16939853
Encephale. 2016 Dec;42(6):511-516
pubmed: 27776797
Addiction. 2002 Sep;97(9):1183-94
pubmed: 12199834
Subst Use Misuse. 2021;56(8):1241-1245
pubmed: 33870867
Pain. 2005 Dec 15;119(1-3):95-103
pubmed: 16298066
JAMA Netw Open. 2019 May 3;2(5):e193365
pubmed: 31050783
Neuropsychopharmacology. 2017 Jan;42(1):129-155
pubmed: 27510422
Mo Med. 2019 Jul-Aug;116(4):318-324
pubmed: 31527982
BMC Med Res Methodol. 2018 Sep 12;18(1):93
pubmed: 30208858
J Clin Psychiatry. 2018 Aug 14;79(5):
pubmed: 30153405
Iran Red Crescent Med J. 2013 Apr;15(4):356-62
pubmed: 24083013

Auteurs

Karam Chamoun (K)

Faculty of Pharmacy, Saint Joseph University of Beirut, Beirut, Lebanon.
Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments, Saint Joseph University of Beirut, Beirut, Lebanon.
Inserm, UMR-S1144, Université Paris Cité, Paris, France.

Joseph Mouawad (J)

Faculty of Pharmacy, Saint Joseph University of Beirut, Beirut, Lebanon.
Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments, Saint Joseph University of Beirut, Beirut, Lebanon.

Pascale Salameh (P)

INSPECT-LB (Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie- Liban), Beirut, Lebanon.
School of Medicine, Lebanese American University, Byblos, Lebanon.
Faculty of Pharmacy, Lebanese University, Hadat, Lebanon.
Department of Primary Care and Population Health, University of Nicosia Medical School, Egkomi, Nicosia, 2417, Cyprus.

Hala Sacre (H)

INSPECT-LB (Institut National de Santé Publique, d'Épidémiologie Clinique et de Toxicologie- Liban), Beirut, Lebanon.

Ramzi Haddad (R)

Psychiatry Department, Faculty of Medical Sciences, Lebanese University, Beirut, Lebanon.
Psychiatry Department, Faculty of Medicine, Saint Joseph University, Beirut, Lebanon.

Lydia Rabbaa Khabbaz (LR)

Faculty of Pharmacy, Saint Joseph University of Beirut, Beirut, Lebanon.
Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments, Saint Joseph University of Beirut, Beirut, Lebanon.

Bruno Megarbane (B)

Inserm, UMR-S1144, Université Paris Cité, Paris, France.
Department of Medical and Toxicological Critical Care, Federation of Toxicology, Lariboisière-Fernand Widal Hospital, Paris, France.

Aline Hajj (A)

Faculty of Pharmacy, Saint Joseph University of Beirut, Beirut, Lebanon. aline.hajj@usj.edu.lb.
Laboratoire de Pharmacologie, Pharmacie Clinique et Contrôle de Qualité des Médicaments, Saint Joseph University of Beirut, Beirut, Lebanon. aline.hajj@usj.edu.lb.
Faculté de Pharmacie, Université Laval, Québec city, Québec, Canada. aline.hajj@usj.edu.lb.
Oncology Division, CHU de Québec- Université Laval Research Center, Québec City, Québec, Canada. aline.hajj@usj.edu.lb.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Opioid use disorder in two samples of the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études transversales › Opioid use disorder in two samples of the...
questionsmedicales.fr › Troubles mentaux › Troubles de l'humeur › Opioid use disorder in two samples of the...
questionsmedicales.fr › Troubles mentaux › Troubles liés à une substance › Troubles liés à l'usage de substances psychotropes › Troubles liés aux opiacés › Opioid use disorder in two samples of the...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Stupéfiants › Analgésiques morphiniques › Opioid use disorder in two samples of the...
questionsmedicales.fr › Phénomènes physiologiques de l'appareil locomoteur et du système nerveux › Phénomènes physiologiques du système nerveux › Sommeil › Opioid use disorder in two samples of the...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Agents du système nerveux central › Dépresseurs du système nerveux central › Hypnotiques et sédatifs › Opioid use disorder in two samples of the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Méthodologie en recherche épidémiologique › Reproductibilité des résultats › Opioid use disorder in two samples of the...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Enquêtes et questionnaires › Opioid use disorder in two samples of the...